Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Gene linked to ectopic pregnancy risk
Wed February 24th - Scientists have identified a gene which may be linked to the risk of ectopic pregnancy. More
Drug-resistant bacteria spread rapidly during travel
Wed February 24th - International travellers are a high risk for transmission of drug resistant bacteria, according to a study published today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For books and family gift ideas click here
RSS graphic XML Graphic

Drug combination hope for breast cancer treatment

Friday March 11th, 2016

Women with HER2 positive breast cancer could see their tumours shrink or disappear altogether if they take a combination of drugs, a conference heard yesterday.

The “ground-breaking” discovery comes after a study found that a quarter of women with the variant saw their tumours shrink significantly or disappear after 11 days when they were treated with a combination of lapatinib and trastuzumab before surgery and chemotherapy.

Speaking at the 10th European Breast Cancer Conference (EBCC-10), in Amsterdam, The Netherlands, yesterday (10 March, 2016), Professor Nigel Bundred told delegates that the offered new scope for personalised treatment.

“This has ground-breaking potential because it allows us to identify a group of patients who, within 11 days, have had their tumours disappear with anti-HER2 therapy alone and who potentially may not require subsequent chemotherapy,” he said, presenting the results from the UK EPHOS-B multi-centre clinical trial.

“This offers the opportunity to tailor treatment for each individual woman.”

Prof Bundred, professor of Surgical Oncology at The University of Manchester and the University Hospital of South Manchester NHS Foundation Trust (UK), said the study focused on 257 women who had newly-diagnosed, operable, HER2 positive disease between November 2010 and September 2015. Some had stage 2 breast cancer.

In the first part of the study, 130 participants were randomly selected to receive no pre-operative treatment (the control group), or trastuzumab (Herceptin) only, or lapatinib (Tyverb) only, for 11 days after diagnosis and before surgery.

As evidence emerged from other trials as to the success of the combination of lapatinib and trastuzumab to treat HER2 positive breast cancer, the second part of the trial was amended so that, from August 2013, the next 127 women were randomised to the control group, or to receive trastuzumab only, or the combination treatment. For both parts of the trial, the women continued to receive standard of care treatment after surgery.

Samples of tumour tissue were taken from the first biopsy and were analysed to see if there had been a drop in levels of the Ki67 protein, an indicator of cell proliferation, or a rise in apoptosis (programmed cell death) of 30% or more from the time of the first biopsy.

Researchers also examined pathology reports on the tissue taken during surgery, and the women were then categorised as either having pathological complete response (pCR) if no active cancer cells had been found, minimal residual disease (MRD) if the tumour was less than 5mm in diameter, or other.

Results from the second part of the trial, analysed in February 2016, showed that, in addition to observing a drop in Ki67 for women who received the combination treatment, 11% had pCR and 17% had MRD.

For those women randomised to receive only trastuzumab, 0% had pCR and 3% had MRD and no patients had either pCR or MRD in the control group.

Professor Judith Bliss, lead researcher from The Institute of Cancer Research, London, which co-led the trial, said: “These results show that we can get an early indication of pathological response within 11 days, in the absence of chemotherapy, in these patients on combination treatment. Most previous trials have only looked at the pathological response after several months of treatment.

“Clearly these results need further confirmation, but I suspect the excitement from seeing the speed of disappearance of the tumours will mean that several trials will attempt to confirm these results.”

Abstract no: 6 LBA. “Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer – the UK EPHOS-B trial (CRUK/08/002)”.

Tags: Cancer | Europe | Pharmaceuticals | UK News | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)